US EditionIASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at Both ANA and ECTRIMS 2025
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
IASO Biotherapeutics to Present Research on Equecabtagene Autoleucel for Multiple Sclerosis at ANA and ECTRIMS 2025 Conferences
IASO Biotherapeutics has announced findings from its re […] The post IASO Biotherapeutics to Present Research on Equecabtagene Autoleucel for Multiple Sclerosis at ANA and ECTRIMS 2025 Conferences first appeared on GeneOnline News. The post IASO Biotherapeutics to Present Research on Equecabtagene Autoleucel for Multiple Sclerosis at ANA and ECTRIMS 2025 Conferences appeared first on GeneOnline News.
IASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at both ANA and ECTRIMS 2025
PLEASANTON, Calif., Sept. 12, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced promising results of its independently developed fully human anti-BCMA CAR-T cell therapy…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
